On Jan. 14, HHS said it would update its guidelines to exempt physicians from the X waiver, a requirement mandated by Congress in 2000 that necessitates physicians receive a day’s training before they can prescribe buprenorphine, a drug that treats opioid addiction and chronic pain. Before he was elected, President Biden’s plan to end the opioid crisis supported this measure.
However, since President Biden took office, legal experts warned the administration that HHS is not authorized to issue guidelines that allow physicians to avoid requirements Congress mandated, sources told the newspaper.
“On January 14, 2021, HHS announced forthcoming practice guidelines for the administration of buprenorphine for treating opioid use disorder. Unfortunately, the announcement was made prematurely. Therefore, the guidelines previously announced cannot be issued at this time,” a message from the White House’s drug policy office obtained by the Washington Post reads.
More articles on pharmacy:
Oklahoma trying to give back $2M hydroxychloroquine stockpile
Sanofi to manufacture 125M doses of Pfizer’s COVID-19 vaccine
Most pregnant women shouldn’t get COVID-19 vaccines, WHO says
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
